MSD launches Clostridium difficile antitoxin in the UK
MSD has launched Zinplava in the UK, offering patients a novel therapeutic option for the prevention of Clostridium difficile recurrence.
Read More
Tag: bezlotoxumab
US nod for Merck’s C.difficile antitoxin
The US Food and Drug Administration has cleared Merck’s Clostridium difficile (CDI) recurrence jab Zinplava after having extended the review period by three month.
Read More
US delay to Merck’s C.difficile antitoxin
Merck & Co’s investigational clostridium difficile treatment has been hit with a setback in the US after regulators extended the review time for the drug by three months.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
